Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 61

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 3
Chunk 61
---
 unenforceable, the Company could be required to:

• bear the potentially significant costs of proceedings brought against us;

• pay damages, which may include treble damages and attorney’s fees if the Company is found to have willfully infringed a third party’s patent rights;

• cease developing, manufacturing and commercializing the infringing technology or product candidates; and

• acquire a license to such third-party intellectual property rights, which may not be available on commercially reasonable terms, or at all, and may be non-exclusive, thereby giving the Company's competitors and other third parties access to the same technologies licensed to us.

Even if resolved in Innate's favor, litigation or other intellectual property proceedings may cause Innate to incur significant expenses and could distract its management and other personnel from their normal responsibilities. For example, Orega Biotech claims joint ownership of certain patents relating to IPH5201, which the Company disputed. As a result of a decision rendered by the arbitral tribunal in December 2021, the Company will be required to pay a low-teen percentage to Orega Biotech on a going forward basis of sub-licensing revenues received by the Company pursuant to its agreement with AstraZeneca regarding IPH5201, and the Company may be obligated to pay Orega Biotech additional amounts upon the achievement of development and regulatory milestones under such agreement. See Note 6 to the consolidated financial statements included under "Item 18. Financial Statements" of this Annual Report. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of Innate's ordinary shares or ADSs. The Company may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of Innate's competitors may be able to sustain the costs of such litigation or proceedings more effectively than Innate can because of their greater financial resources and more mature and developed intellectual property portfolios. Should one or more of the foregoing risks materialize, this could have a material adverse effect on Innate's reputation, business, prospects, financial condition and results of operations.

Its patents could be found invalid or unenforceable if challenged, and the Company may not be able to protect its intellectual property.

Innate's and its licensors’ patents and patent applications, if issued, may be challenged, invalidated or circumvented by third parties. U. S. patents and patent applications may